BioCardia, Inc. Common Stock
$1.11
-$0.14 (-11.20%)
$1.10Day Range$1.26
Key Statistics
Market Cap
$16.80M
Shares Outstanding
15.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 25, 1995
Round Lot
100
Locale
US
Trading Data
Day Open
$1.25
Day High
$1.26
Day Low
$1.10
Volume
417.3K
VWAP
$1.17
Prev Close
$1.25
Transactions
--
Acc. Volume
--
About BioCardia, Inc. Common Stock
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283621 employees320 SOQUEL WAY, SUNNYVALE, CA, 94085650-226-0123IPO Oct 25, 1995US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000925741
- Composite FIGI
- BBG000BTJTF3
- Share Class FIGI
- BBG001S72MS0
- Ticker Root
- BCDA
- SIC Code
- 2836
About BioCardia, Inc. Common Stock (BCDA) Stock
BioCardia, Inc. Common Stock (BCDA) closed the 2026-09-17 session at $1.11, down 11.20% versus the previous close (-0.14). The stock opened at $1.25 and traded between $1.10 and $1.26 during that session. Session trading volume was 417K shares. The volume-weighted average price (VWAP) is $1.17.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
BioCardia, Inc. Common Stock has a market capitalization of $16.8 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. BCDA is listed on the XNAS exchange. The company employs approximately 21 people. BioCardia, Inc. Common Stock is headquartered in SUNNYVALE, CA. The recorded listing date is 1995-10-25.
On this page you can find market BCDA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.